Segment and Related Information

3 Months Ended

Sep. 30, 2019

(16)	SEGMENT AND RELATED INFORMATION

The Company’s business is aligned with how the Chief Operating Decision Maker reviews performance and makes decisions in managing the Company. The business units have been aggregated into two reportable segments: (i) diagnostics and (ii) other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology.

Segment revenue and operating income (loss) were as follows during the periods presented:

	Diagnostics		Other			Total
Three months ended September 30, 2019
Revenues	$	170.4	$	15.9		$	186.3
Depreciation and amortization		16.9		1.3			18.2
Segment operating income (loss)		17.3		(38.2	)		(20.9	)
Three months ended September 30, 2018
Revenues	$	189.0	$	13.3		$	202.3
Depreciation and amortization		17.0		1.3			18.3
Segment operating income		27.6		(26.4	)		1.2

	Three months ended
	September 30,
	2019			2018
Total operating income for reportable segments	$	(20.9	)	$	1.2
Unallocated amounts:
Interest income		0.9			0.7
Interest expense		(2.9	)		(2.2	)
Other		0.6			1.1
Income (loss) from operations before income taxes		(22.3	)		0.8
Income tax provision		(1.7	)		1.6
Net income (loss)		(20.6	)		(0.8	)
Net loss attributable to non-controlling interest		—			(0.1	)
Net income (loss) attributable to Myriad Genetics, Inc. stockholders	$	(20.6	)	$	(0.7	)